Dopamine D2S and D2L receptors may differentially contribute to the actions of antipsychotic and psychotic agents in mice (original) (raw)
Antipsychotic drugs which elicit little or no Parkinsonism bind more loosely than dopamine to brain D2 receptors, yet occupy high levels of these receptors
P. Seeman
Molecular Psychiatry, 1998
View PDFchevron_right
Dopamine D(2) receptor occupancy is a common mechanism underlying animal models of antipsychotics and their clinical effects
Alexandra Soliman
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2001
View PDFchevron_right
F15063, a potential antipsychotic with dopamine D2/D3 antagonist, 5-HT1A agonist and D4 partial agonist properties: (IV) duration of brain D2-like receptor occupancy and antipsychotic-like activity versus plasma concentration in mice
Ronan Depoortere, Adrian Newman-Tancredi, Agnès Auclair
Naunyn-Schmiedeberg's Archives of Pharmacology, 2007
View PDFchevron_right
Half a century of antipsychotics and still a central role for dopamine D2 receptors
David Mamo
Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2003
View PDFchevron_right
Intrinsic Efficacy of Antipsychotics at Human D2, D3, and D4 Dopamine Receptors: Identification of the Clozapine Metabolite N-Desmethylclozapine as a D2/D3 Partial Agonist
Norman Nash
Journal of Pharmacology and Experimental Therapeutics, 2005
View PDFchevron_right
D-amphetamine and antipsychotic drug effects on Latent Inhibition in mice lacking dopamine D2 receptors
Paula Moran
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2013
View PDFchevron_right
Dopamine D2 heteroreceptor complexes and their receptor-receptor interactions in ventral striatum: Novel targets for antipsychotic drugs
Wilber Romero-Fernandez, Michael Di Palma, Sergio Tanganelli, Dasiel O Borroto-Escuela, Luigi Agnati
2014
View PDFchevron_right
The Importance of Dopamine D4 Receptors in the Action and Development of Antipsychotic Agents
Gavin Reynolds
Drugs, 1996
View PDFchevron_right
Identification and Characterization of ML321: a Novel and Highly Selective D2Dopamine Receptor Antagonist with Efficacy in Animal Models that Predict Atypical Antipsychotic Activity
William Wetsel
View PDFchevron_right
Endogenous dopamine limits the binding of antipsychotic drugs to D3 receptors in the rat brain: a quantitative autoradiographic study
Josee Leysen
The Histochemical Journal, 1996
View PDFchevron_right
Novel Dopamine Receptor Subtypes as Targets for Antipsychotic Drugs
Jorge Diaz
Annals of the New York Academy of Sciences, 1995
View PDFchevron_right
The Effect of Antipsychotics on the High-Affinity State of D2 and D3 Receptors
Ariel Graff-Guerrero
Archives of General Psychiatry, 2009
View PDFchevron_right
Potential Mechanisms for Why Not All Antipsychotics Are Able to Occupy Dopamine D3 Receptors in the Brain in vivo
Dr. István Laszlovszky
Frontiers in Psychiatry
View PDFchevron_right
Antipsychotic efficacy: Relationship to optimal D 2-receptor occupancy
Giorgio Marchese
European Psychiatry, 2007
View PDFchevron_right
Dopamine D2 Long Receptor-Deficient Mice Display Alterations in Striatum-Dependent Functions
Toshikuni Sasaoka
The Journal of Neuroscience the Official Journal of the Society For Neuroscience, 2000
View PDFchevron_right
Receptor reserve-dependent properties of antipsychotics at human dopamine D2 receptors
Robert McQuade
European Journal of Pharmacology, 2009
View PDFchevron_right
Medial prefrontal cortical D2 and striatolimbic D4 dopamine receptors : Common targets for typical and atypical antipsychotic drugs
Ross Baldessarini
Progress in Neuro Psychopharmacology Biological Psychiatry, 1998
View PDFchevron_right
Atypical antipsychotic-like effects of the dopamine D3 receptor agonist, (+)-PD 128,907
Durk Dijkstra
European Journal of Pharmacology, 1998
View PDFchevron_right
In vivo occupancy of dopamine D2 receptors by antipsychotic drugs and novel compounds in the mouse striatum and olfactory tubercles
Adrian Newman-Tancredi
Naunyn-Schmiedeberg's Archives of Pharmacology, 2006
View PDFchevron_right
Subnanomolar dopamine D3 receptor antagonism coupled to moderate D2 affinity results in favourable antipsychotic-like activity in rodent models: II. behavioural characterisation of RG-15
Béla Kiss
Naunyn-Schmiedeberg's Archives of Pharmacology, 2008
View PDFchevron_right
Identification and Characterization of ML321: a Novel and Highly Selective D2Dopamine Receptor Antagonist with Efficacy in Animal Models that Predict Atypical Antipsychotic Activity
Ramona Rodriguiz
bioRxiv (Cold Spring Harbor Laboratory), 2022
View PDFchevron_right
Dopamine D3 receptor as a therapeutic target for antipsychotic and antiparkinsonian drugs
Jeffrey Joyce
Pharmacology & Therapeutics, 2001
View PDFchevron_right
Antagonism of dopamine D2 receptor/ -arrestin 2 interaction is a common property of clinically effective antipsychotics
Bernard Masri
Proceedings of the National Academy of Sciences, 2008
View PDFchevron_right
Occupancy of dopamine D2 receptors by the atypical antipsychotic drugs risperidone and olanzapine: theoretical implications
Anissa Abi-Dargham
Psychopharmacology, 2004
View PDFchevron_right
Possible implications of the dopamine D 3 receptor in schizophrenia and in antipsychotic drug actions
Jorge Diaz
Brain Research Reviews, 2000
View PDFchevron_right
Long-Term Effects of S(+)N-n-Propylnorapomorphine Compared with Typical and Atypical Antipsychotics: Differential Increases of Cerebrocortical D2-Like and Striatolimbic D4-Like Dopamine Receptors
Ross Baldessarini
Neuropsychopharmacology, 1997
View PDFchevron_right